Study of BEBT-908 in the Relapsed or Refractory Diffuse Large B-cell Lymphoma Subjects
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Clinical Trials Related to Relapsed or Refractory Diffuse Large B-cell Lymphoma
Related studies linked through entity extraction aliases.
A Study to Evaluate Zilovertamab Vedotin (MK-2140) for Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) (MK-2140-004)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Study of Selinexor in Combination With Backbone Treatments or Novel Therapies In Participants With Relapsed or Refractory (RR) Diffuse Large B-Cell Lymphoma (DLBCL)
- Status
- WITHDRAWN
- Phase
- PHASE1/PHASE2
A Phase Ib Combination Study of Rituximab, TinostamustinEAnd CHeckpoint Inhibition With Pembrolizumab in Relapsed/Refractory DLBCL
- Status
- WITHDRAWN
- Phase
- PHASE1
A Phase 1 Trial of OPB-111077 in Combination With Bendamustine and Rituximab in Patients With r/r DLBCL
- Status
- COMPLETED
- Phase
- PHASE1